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Clinical prospects for human induced pluripotent 
stem cells
Th  e ﬁ   rst reports of the generation of human induced 
pluripotent stem cells (hiPSCs) from ﬁ  broblasts  [1,2] 
were greeted with great enthusiasm over their ability to 
mimic the properties and function of embryonic stem 
cells without entailing the ethical controversies and 
resourcing issues associated with the use of human 
blastocysts in derivation. In the several years since those 
ﬁ  rst reports, new advances in the derivation of hiPSCs 
from various tissue sources (including those from human 
patients) and using diverse reprogramming techniques, 
and in their use as a pluripotent cell source in the induced 
diﬀ  erentiation of a wide array of somatic cell types, have 
appeared with almost startling rapidity. At least one 
biotech company (iPierian) has been founded to exploit 
the commercial potential of these reprogramming tech-
nologies, and the Japanese government has established 
an entire research institute dedicated to fundamental and 
applied iPSC research (Center for iPS Cell Research and 
Application, Kyoto University). Clearly, the early expecta-
tions surrounding iPSCs have been extraordinary.
A number of recent articles, however, have reported 
that hiPSCs are, in fact, notably distinct from human 
embryonic stem cells in terms of their gene expression, 
epigenetic proﬁ  le, proliferative capacity and the suscep-
tibility of their diﬀ  erentiated progeny to cellular senes-
cence and apoptosis [3-6]. Additionally, the head of a 
prominent human embryonic stem cells ﬁ  rm (Geron) has 
publicly questioned the viability of commercialized 
therapeutic applications of autologous hiPSCs due to the 
regulatory requirements imposed by the US Food and 
Drug Administration [7]. Th   e important question now is 
whether these barriers are high enough to preclude the 
translation of fundamental hiPSC discoveries into cellular 
therapies.
As for any innovation with potential medical applica-
tions, hiPSCs must satisfy a great number of criteria prior 
to their introduction into clinical practice. First and 
foremost come issues of safety and eﬃ   cacy. Th  e  earliest 
methods for the induction of iPSCs relied on the use of 
viral vectors, which are encumbered by risks of inser-
tional mutagenesis and transgene reactivation. Numerous 
alternative methods for inducing pluripotency without 
the use of gene insertion have been reported, and 
although their eﬃ     ciency remains problematic, if the 
current rate of progress in methodology continues, these 
should make it possible to bypass some of the primary 
safety concerns. But others will still remain, such as the 
long-term karyotypic stability, appropriate in situ
localiza  tion, and potential for wayward diﬀ  erentiation of 
somatic cells derived from hiPSCs. Several excellent 
overviews of the scientiﬁ   c challenges confronting cell 
therapy have described these issues in detail [8-11].
Of course, safety alone does not guarantee eﬃ   cacy. 
Despite promising results from animal studies, the 
viability of the cell transplantation paradigm in human 
has been demonstrated in only a few contexts, mainly 
involving the use of hematopoietic stem cell transplants, 
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recellularization of decellularized or engineered tissue. 
For hiPSCs, or any stem cells used as a source of human 
somatic cells, to be therapeutically eﬀ   ective in trans-
plantation it needs to be shown that their progeny will 
function normally in the intended site for signiﬁ  cant 
periods of time, which will require extensive testing ﬁ  rst 
in animals, and then in appropriately designed (ideally in 
randomized, double-masked, multi-site) clinical trials.
Such trials are inevitably costly, and the traditional 
strategy for drug development suggests one means of 
undertaking these development expenses is for well-
funded companies to lead the way, motivated by the 
potential return on investment to be gained from a 
successful proprietary therapy. However, with few 
exceptions, the stem cell and regenerative medicine 
industry has remained inadequately capitalized to carry 
out large-scale clinical trials independently, and major 
pharmaceutical ﬁ  rms have tended to show more interest 
in the use of hiPSCs as a source of large, pure populations 
of speciﬁ   c somatic cells for use in drug compound 
screening and toxicology tests, than they have in 
therapeutic uses of stem cells and their derivatives.
Th  is reluctance is due in part to the great many 
unanswered questions over the viability of cell therapy 
business models. At the production stage, issues of end-
product standardization and purity, scalability, and 
timeliness have yet to be worked out. Similarly, delivery 
systems for ensuring integration of hiPSC-derived 
cellular populations must be developed and tested. Even 
beyond these technical issues lie a host of purely business 
concerns, including intellectual property, cost-eﬀ  ective-
ness, and regulatory aﬀ   airs. Interested readers are 
directed to comprehensive reviews of cell medicine 
business models [12,13].
Despite these many hurdles and the newness of the 
technology, there are already some glimmers of hope for 
clinical applications of hiPSCs. Diseases of the retina may 
oﬀ  er an early test bed for hiPSC-derived cells, in the form 
of retinal pigmented epithelium, given the relative 
isolation of the tissue, and the small number of cells 
required [14]. A second intriguing possibility would be 
the use of hiPSCs to produce functional cells for use in 
extra-corporeal applications, such as mature hepatocytes 
for use in bio-artiﬁ  cial livers. If such early applications 
prove successful, it may help to allay concerns over safety 
and increase public and regulatory acceptance of the 
clinical use of hiPSCs, enabling them to establish a solid 
footing before attempts are made at treating more 
complex and deeply rooted disorders.
At the same time, it will be important for cell therapy 
pioneers to investigate alternative routes for funding 
their work, so as to ensure the standards of safety and 
eﬃ     cacy expected of small molecules are also met by 
cellular applications. In countries with socialized 
healthcare, governments have a strong interest in 
obtaining access to low-cost and eﬀ  ective  long-term 
remedies, and may prove willing to invest in research and 
development if the economics of the cell therapy strategy 
are shown to be attractive. Japan has taken some steps in 
this direction, both in establishing the ﬁ  rst  centre 
dedicated entirely to hiPSC research, with an emphasis 
on application, and by publishing a draft of what looks to 
be the world’s ﬁ  rst governmental regulations speciﬁ  cally 
focused on hiPSC-derived cell safety and quality [15].
As can be seen, a great many issues must be resolved 
before hiPSCs can be responsibly introduced to the 
clinic. But it is important to stress that such hurdles have 
confronted other ﬂ  edgling technologies that subsequently 
revolutionized medicine as well. None of the diﬃ   culties 
confronting hiPSCs appears to be inherently 
insurmountable, and given the revolutionary advances 
that successful applications of reprogramming and cell 
transplantation might one day bring, it would seem that, 
for now, the sustained investment of suﬃ   cient  eﬀ  ort, 
capital and time remain imperative.
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